MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 31, 2008; DOI: 10.1124/mol.108.048900


0026-895X/08/7405-1372-1380$20.00
Mol Pharmacol 74:1372-1380, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.048900v1
74/5/1372    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paproski, R. J.
Right arrow Articles by Cass, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paproski, R. J.
Right arrow Articles by Cass, C. E.

The Role of Human Nucleoside Transporters in Uptake of 3'-Deoxy-3'-fluorothymidine

Robert J. Paproski, Amy M. L. Ng, Sylvia Y. M. Yao, Kathryn Graham, James D. Young, and Carol E. Cass

Departments of Oncology (R.J.P., K.G., C.E.C.) and Physiology (A.M.L.N., S.Y.M.Y., J.D.Y.), University of Alberta, and the Cross Cancer Institute, Edmonton, Alberta, Canada (R.J.P., K.G., C.E.C.)

3'-Deoxy-3'-fluorothymidine (FLT) is a positron emission tomography (PET) tracer used to identify proliferating tumor cells. The purpose of this study was to characterize FLT transport by human nucleoside transporters (hNTs) and to determine the role of hNTs for FLT uptake in various human cancer cell lines. FLT binding to hNTs was monitored by the inhibitory effects of FLT on [3H]uridine uptake in yeast cells producing recombinant hNT proteins. hCNT1 displayed the lowest FLT Ki value for inhibition of [3H]uridine uptake, followed by hCNT3, hENT2, hENT1, and hCNT2. [3H]FLT was efficiently transported in Xenopus laevis oocytes individually producing hENT1, hENT2, hCNT1, or hCNT3. [3H]FLT uptake in MCF-7, A549, U251, A498, MIA PaCa-2, and Capan-2 cells was inhibited at least 50% by the hENT1 inhibitor nitrobenzylmercaptopurine ribonucleoside (NBMPR). According to results of real-time polymerase chain reactions, hENT1 and hENT2 had the most abundant hNT transcripts in all cell lines. Cell lines also underwent 1) [3H]NBMPR equilibrium binding assays with or without 5-S-{2-(1-[(fluorescein-5-yl)thioureido]hexanamido)ethyl}-6-N-(4-nitrobenzyl)-5-thioadenosine, a membrane-impermeable NBMPR analog, to determine plasma membrane hENT1 levels, and 2) dose-response NBMPR inhibition of [3H]FLT uptake. MCF-7, A549, and Capan-2 cells displayed NBMPR IC50 values that were smaller or equal to NBMPR Kd values, suggesting that 50% inhibition of hENT1 reduced [3H]FLT uptake by at least 50%. A strong correlation between extracellular NBMPR binding sites/cell and [3H]FLT uptake was observed for all cell lines except MIA PaCa-2. These data suggest that plasma membrane hNTs (especially hENT1) are important determinants of cellular FLT uptake.


Received May 16, 2008; accepted July 30, 2008

Address correspondence to: Dr. Carol E. Cass, Department of Oncology, University of Alberta, Cross Cancer Institute, 11560 University Ave., Edmonton, Alberta, Canada T6G 1Z2. E-mail: carol.cass{at}cancerboard.ab.ca







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics